ClinicalTrials.gg
CompletedNCT04145596Updated Dec 17, 2020

Safety and Pharmacokinetics/Pharmacodynamics of HSK3486 in Patients With Hepatic Impairment

A Phase 1 interventional study of HSK3486 in Hepatic Impairment, sponsored by Sichuan Haisco Pharmaceutical Group Co., Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-12-17.

Sponsored by Sichuan Haisco Pharmaceutical Group Co., Ltd (part of Haisco Pharmaceutical Group Co., Ltd.) · Phase 1, Interventional, and Diagnostic

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years to 64 Years
Sex
All
01

Study summary

Comparison of the pharmacokinetics/Pharmacodynamics of the HSK3486 in Patients With Mild and Moderate Hepatic Impairment Compared with Healthy Volunteers

Read the detailed description

This is a single-center, open-label, non-randomized, parallel-controlled Phase I clinical study carried out in patients with compensated chronic liver disease (Child-Pugh A), patients with decompensated chronic liver disease (Child-Pugh B), and age-, weight-, and gender-matched subjects with normal liver functions.

02

Conditions studied

  • Hepatic Impairment
03

In context

Lead sponsor

Sichuan Haisco Pharmaceutical Group Co., Ltd is the lead sponsor of 30 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Sign the form and fully understand the content, procedure and possible adverse effects before the trial starts;
  2. Able to complete the study in compliance with the requirements of the clinical trial protocol;
  3. Subjects (including their partners) are willing to voluntarily adopt an effective measure of starting from screening to 6 months after the last dose of the drug.
  4. Male or female subjects aged 18-64 years old (including 18 and 64 years old);
  5. Male subjects weighing ≥ 50 kg, female subjects weighing ≥ 45 kg; (BMI) = weight (kg)/height2 (m2); BMI of ≥ 18 and ≤ 30 kg/m2 (inclusive);
  6. Blood pressure between 90-149/60-94 mmHg (inclusive); heart rate between 55-100 bpm (inclusive); body temperature between 35.9-37.6°C (inclusive); respiratory rate between 12-20 breaths per min (inclusive); SpO2 when inhaling ≥ 95%;
  7. Normal physical examination results or abnormal physical examination results with no clinical significance;
  8. For subjects with normal liver functions, their clinical laboratory tests (blood routine, blood biochemistry, urine routine, and coagulation function) should be normal or abnormal without clinical significance;
  9. No potential difficult airway (modified Mallampati score of Grade I to II);
  10. For subjects with normal liver functions, they should have no history of primary diseases in major organs, including but not limited to gastrointestinal, respiratory, renal, hepatic, neurological, hematological, , endocrine, oncological, immunological, psychiatric or cardiovascular and cerebrovascular diseases;

    Patients with Hepatic Insufficiency Must Also Meet the Following Inclusion Criteria:

  11. grade A or B hepatic insufficiency caused by previous primary liver diseases: including non-alcoholic steatohepatitis and viral hepatitis (, );
  12. The liver function is determined by the investigators as stable within 14 days before drug administration;
  13. Have not used any drug or dosing regimen within 4 weeks before screening that can stabilize the primary liver disease.

Exclusion criteria

Exclusion Criteria:

  1. Have not used any drug or dosing regimen within 4 weeks before screening that can stabilize the primary liver disease;
  2. Patient having to deep sedation/general anesthesia or a history of past sedation/anesthesia accidents;
  3. Known sensitivity to in HSK3486 injectable emulsion (soybean oil, glycerin, triglyceride, egg lecithin, sodium oleate and sodium hydroxide); or with allergic constitution (including history of drug allergies and allergic diseases);
  4. History of alcohol abuse (> 2 units of alcohol consumed per day: 1 unit = 285 mL of beer, or 25 mL of liquor, or 100 mL of wine) within 3 months prior to screening;
  5. History of drug abuse within 3 months prior to screening, or a history of long-term use of benzodiazepines;
  6. Blood/plasma donation or blood loss of ≥ 200 mL, or plasma exchange within 30 days prior to screening;
  7. In receipt of prescription drugs, Chinese herbal medicines, over-the-counter drugs or food supplements (such as vitamins and calcium supplements) other than , paracetamol, non-steroidal anti-inflammatory drugs, topical over-the-counter preparations, within 2 weeks prior to screening (patients with hepatic insufficiency can also use drugs for treating primary liver diseases);
  8. Participated in other drug/medical device trials within 3 month prior to screening;
  9. Patients with abnormalities in (such as tachycardia/bradycardia requiring medication, II-III degree atrioventricular block or interval ≥ 450 ms (Fridericia's correction formula), or other clinically significant abnormalities determined by the clinician);
  10. Female subjects in lactation or having positive serum pregnancy test results during the screening period or the trial;
  11. Positive screening result of any indicators of surface antigen, antibody or hepatitis C core antigen, antibody, or syphilis antibody (hepatitis B surface antigen, hepatitis C antibody or hepatitis C core antigen may be positive for patients with hepatic insufficiency);
  12. Subjects with serious or clinically significant infections (such as infections of the respiratory tract or central nervous system), trauma, or major surgery within 4 weeks prior to screening;
  13. Subjects expected to have surgery or hospitalization during the trial;
  14. Subjects who have consumed any beverages or foods containing alcohol (or positive alcohol breath test results), grapefruit juice or methylxanthine (such as coffee, tea, cola, chocolate, and functional drinks), participated in strenuous physical activities, and with other factors that may affect drug absorption, distribution, metabolism, and excretion within 1 day prior to dose administration;
  15. Subjects with positive urine drug screening results (morphine, methamphetamine, ketamine, marijuana, ecstasy pills);
  16. Subjects unsuitable for arterial blood collection, such as subjects who have positive Allen's test results;
  17. Subjects who are unable to fast for 8 hrs before dose administration;
  18. Subjects who have used propofol, other sedatives/anesthetics, and/or opioid analgesics or compounds containing analgesics within 72 hrs prior to dose administration;
  19. Subjects judged by the investigator to be unsuitable for participating in this trial for any reason.

    The Following Exclusion Criteria are Added for Patients with Hepatic Insufficiency:

  20. Clinical laboratory abnormalities with clinical significance, or other clinical findings showing the following illnesses with clinically significance, including but not limited to gastrointestinal, respiratory, renal, neural, hematological, endocrine, neoplastic, immunological, psychiatric or cardiovascular and cerebrovascular diseases other than primary liver diseases;
  21. Patients with liver failure, or with cirrhotic combined with hepatic encephalopathy, hepatocellular carcinoma, and esophageal and gastric variceal bleeding and other complications considered by the investigator as unsuitable for the clinical study;
  22. History of liver transplantation.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Active comparator
    Compensated Chronic Liver Disease (Child-Pugh A)

    Drug: HSK3486

  • Active comparator
    Decompensated Chronic Liver Disease (Child-Pugh B)

    Drug: HSK3486

  • Active comparator
    healthy volunteers(Normal liver functions)

    Drug: HSK3486

Interventions

  • HSK3486,Initially 0.4 mg/kg was administered as a 1 minute bolus, followed immediately by a constant infusion dose of 0.4 mg/kg/h administered as a 30 minute infusion via infusion pump.

06

What researchers measure

Primary outcomes

  1. Peak concentration (Cmax)

    Cmax(a measure of the body's exposure to HSK3486)will be compared between normal hepatic function patients and Patients with Compensated Chronic Liver Disease (Child-Pugh A) or Patients with Decompensated Chronic Liver Disease (Child-Pugh B).

    Time frame: -30 minutes before administration until 24 hours post administration on day 1

  2. Area under the concentration-time curve (AUC)

    AUC(a measure of the body's exposure to HSK3486)will be compared between normal hepatic function patients and Patients with Compensated Chronic Liver Disease (Child-Pugh A) or Patients with Decompensated Chronic Liver Disease (Child-Pugh B).

    Time frame: -30 minutes before administration until 24 hours post administration on day 1

Secondary outcomes

  1. MOAA/S(modified observer's assessment of alert /sedation)

    Time frame: -5 minutes before administration until 1 hours post administration on day 1

  2. Bispectral index(BIS)

    Time frame: -5 minutes before administration until 1 hours post administration on day 1

  3. Tmax

    time to peak observed

    Time frame: -30 minutes before administration until 24 hours post administration on day 1

  4. Total clearance

    Time frame: -30 minutes before administration until 24 hours post administration on day 1

  5. Volume of distribution

    Time frame: -30 minutes before administration until 24 hours post administration on day 1

  6. blood pressure(systolic, diastolic and mean arterial pressure)

    safety endpoits

    Time frame: from the screening to 3 days post-dose

07

Study locations

1 site
  • Phase I Clinical Trial Laboratory, The First Hospital of Jilin University
    Chang chun, Ji Lin 130021, China
08

References and documents

Publications

  • Qin L, Ren L, Wan S, Liu G, Luo X, Liu Z, Li F, Yu Y, Liu J, Wei Y. Design, Synthesis, and Evaluation of Novel 2,6-Disubstituted Phenol Derivatives as General Anesthetics. J Med Chem. 2017 May 11;60(9):3606-3617. doi: 10.1021/acs.jmedchem.7b00254. Epub 2017 Apr 28. PubMed 28430430 ↗
  • Hu Y, Li X, Liu J, Chen H, Zheng W, Zhang H, Wu M, Li C, Zhu X, Lou J, Yan P, Wu N, Liu X, Ma S, Wang X, Ding Y, Xuan C. Safety, pharmacokinetics and pharmacodynamics of a novel gamma-aminobutyric acid (GABA) receptor potentiator, HSK3486, in Chinese patients with hepatic impairment. Ann Med. 2022 Dec;54(1):2769-2780. doi: 10.1080/07853890.2022.2129433. PubMed 36217101 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2019 to primary completion in Apr 2020, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2019
First posted
Oct 30, 2019
StartActual
Nov 14, 2019
Primary completionActual
Apr 20, 2020
CompletionActual
Jul 13, 2020
Last update
Dec 17, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 17, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04145596
Responsible party
Sponsor
First posted
Oct 30, 2019
Start date
Nov 14, 2019
Primary completion
Apr 20, 2020
Completion
Jul 13, 2020
Last update
Dec 17, 2020

Study contacts

Yan-hua Ding, PhD
study director · Phase I Clinical Trial Laboratory,The First Hospital of Jilin University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ciprofol

Start the discussion